Gilead Sciences, Inc. (GILD) Price and Market Data

Gilead Sciences Inc develops and commercializes therapies for the treatment and prevention of life-threatening infectious diseases, with a core portfolio centered on HIV and hepatitis B and C. The company’s acquisition of Pharmasset secured the rights to the hepatitis C drug Sovaldi, which also features in newer combination regimens that continue to serve as standards of care. Gilead is also expanding its presence in oncology through acquisitions, led by the CAR-T cell therapies Yescarta and Tecartus from Kite, as well as the breast and bladder cancer treatment Trodelvy from Immunomedics.